Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-ranging study of brivekimig in adults with moderate to severe Crohn's disease
CTR20253563Phase 2Active
- Sponsor
- Sanofi
- Start
- Sep 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of brivekimig in Crohn's disease, sponsored by Sanofi. Started Sep 2025; status: active.
02
Drugs
brivekimig
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20253563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253563.